Citius Oncology, Inc.

NASDAQ:CTOR

Drug Manufacturers - General

Healthcare
$0.56 +4.23%

+$0.03 today

Market cap
$51.83M
Beta
3.42
P/E (TTM)
-1.6
EPS (TTM)
-$0.42
52W Low $0.49High $6.19

Volume 0.15M

Average 0.12M

CTOR Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Citius Oncology, Inc.NASDAQ: CTOR

Accounts Receivables · Q2 FY2026 · quarter ended Mar 2026

Accounts receivables outflow grows to $2.96M

Q2 FY2026 accounts receivables was $2.96M, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was -$1.09M.

Context

  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $2.96M or moves back toward the trailing-twelve-month quarterly average of -$273.05K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.96M+173.0% QoQ
Last fiscal yearSep 2025
$0— YoY
LTMMar 2026
-$1.09M— YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Accounts Receivables vs competitors

How CTOR compares with its peers on the latest reported figures

  • CTOR's LTM Mar 2026 accounts receivables of $1.09M is the 6th largest of the 10 companies compared; the peer median is $624K.
  • Accounts receivables amounts to 19.5% of revenue for CTOR, versus a peer median of 5.6%.
CTOR Competitors Peer median
Accounts Receivables for CTOR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OWLTOwlet, Inc.LTM Mar 2026$3.32M -36.0%+8.9%3.1%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$2.53M +162.9%—220.4%
SCLXScilex Holding CompanyLTM Mar 2026$2.42M -48.1%—7.2%
LNSRLENSAR, Inc.LTM Mar 2026$2.39M +188.7%—4.1%
FATEFate Therapeutics, Inc.LTM Mar 2026$1.7M +279.7%—26.9%
CTORCitius Oncology, Inc.LTM Mar 2026$1.09M ——19.5%
SPROSpero Therapeutics, Inc.LTM Mar 2026$624K -85.7%+25.5%1.1%
FBRXForte Biosciences, Inc.LTM Mar 2026$0 ———
VORVor Biopharma Inc.LTM Mar 2026$0 ———
ACTUActuate Therapeutics IncLTM Mar 2026$0 ———
Peer median (excluding CTOR) $624K+63.5%+17.2%5.6%

Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income380.81K2.42M(21.15M)(24.76M)
Depreciation & Amortization0000
Deferred Income Tax00576K1.06M
Stock-Based Compensation0000
Change in Working Capital64.24K411.77K13.2M9.89M
Accounts Receivables25.99K349.05K00
Inventory00(2.13M)(12.65M)
Accounts Payables002.42M9.52M
Other Working Capital38.25K62.72K12.91M13.02M
Other Non-Cash Items(493.02K)(3.43M)7.5M8.32M
Operating Cash Flow(47.97K)(601.3K)126.35K(5.49M)
Capital Expenditures04(4)(4)
Acquisitions (Net)0000
Purchases of Investments(67.32M)(1.32M)00
Sales of Investments0000
Other Investing Activities00(5M)(5.75M)
Investing Cash Flow(67.32M)(1.32M)(5M)(5.75M)
Debt Repayment003.8M0
Common Stock Issued68.04M0015.17M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(383.84K)1.66M1.07M0
Financing Cash Flow67.66M1.66M4.87M15.17M
Effect of Forex Changes00(32.75K)0
Net Change in Cash289.18K(256.43K)(32.63K)3.92M
Free Cash Flow(47.97K)(601.3K)126.35K(5.49M)

Citius Oncology, Inc.

NASDAQ:CTOR

Intrinsic Alpha fair value

Locked

Current Price

$0.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.